Table 2.

ARCON patient clinicopathologic features by randomization arm

Accelerated radiotherapyARCON
Variablen = 77n = 80P
Gender0.06
 Male55 (71.4%)68 (85%)
 Female22 (28.6%)12 (15%)
Age, y59 (46–82)60 (44–84)0.69
T Stage0.64
 T224 (31.1%)28 (35.0%)
 T337 (48.1%)40 (50.0%)
 T416 (20.8%)12 (15.0%)
N Stage0.33
 N041 (53.2%)54 (67.5%)
 N114 (18.2%)9 (11.3%)
 N2a3 (3.9%)4 (5.0%)
 N2b5 (6.5%)2 (2.5%)
 N2c14 (18.1%)11 (13.7%)
Subsite0.25
 Glottis23 (29.9%)32 (40%)
 Supraglottis54 (70.1%)48 (60%)
Hb (g/L)9.1 (5.8–11.0)9.0 (6.1–10.5)0.64
 No data1 (1.3%)2 (2.5%)
TLDA-HS0.035 (1 × 10−5–0.085)0.031 (9 × 10−5–0.19)0.72

NOTE: Data represented as n (%) or median (range). NB, percent tumor was >30% for all cases.

Abbreviation: Hb, hemoglobin.